Acticor Biotech

Acticor Biotech is a French biopharmaceutical startup with a mission to revolutionize the treatment of acute phase ischemic strokes. Founded in 2010, the company has garnered substantial attention and investment due to its pioneering approach. Acticor Biotech's innovative therapeutic strategy aims to address the urgent need for more effective emergency treatment of ischemic strokes, which account for 80% of all stroke cases. According to the World Health Organization, there are 15 million stroke cases globally each year, resulting in 5 million deaths and another 5 million individuals being permanently disabled. However, only 15% of ischemic stroke patients currently receive the recommended treatment, which exhibits less than 40% efficacy. This underscores the substantial market demand for a more effective solution. The scientific foundation of Acticor Biotech's project is based on the pioneering research of its founders, Dr. M. Jandrot-Perrus and Prof. P. Billiald, and has received support from prestigious institutions including the ANR (The French National Research Agency) and the Fondation de France. The company has also been recognized for its innovation, winning the 2012 national prize for innovation in creation & development from the BPI (French Public Investment Bank). Despite the notable progress, Acticor Biotech has continued to attract significant investment, with a recent €8.00M post-IPO equity investment on 15 March 2024 from investors including UI Investissement, Mediolanum Farmaceutici S.p.A., Alain Munoz, and Gilles Avenard. This level of financial backing underscores confidence in the company's potential to revolutionize stroke treatment and underscores significant interest from key players in the biotechnology and pharmaceutical industries. Acticor Biotech's dedication to addressing an unmet medical need in a high-impact area, combined with impressive financial support and notable partnerships, positions the company as a compelling investment opportunity in the biopharmaceutical sector.